BICILLIN C-R Rx
Generic Name and Formulations:
Penicillin G benzathine, penicillin G procaine equal amounts; combined penicillin G dose 600,000Units/mL; susp for deep IM inj; contains parabens.
Indications for BICILLIN C-R:
Susceptible moderately severe infections including respiratory, skin and soft tissue, erysipelas, scarlet fever, otitis media.
Adults and Children:
C-R: Give by deep IM inj (buttock or, in young children, may give in anterolateral thigh). Group A strep: <30lbs: 600,000 units; 30–60lbs: 900,000–1.2 million units; >60lbs: 2.4 million units; all as single dose (may split injections) or may give one-half total dose on day 1 and one-half on day 3. Pneumococcal (except meningitis) children: 600,000 units; adults 1.2 million units; give every 2–3 days until afebrile for 48 hrs.
Avoid intraarterial, intravascular, and intraneural inj.
Not for IV use. Do not admix with other IV solutions. Reports of inadvertent IV administration has been associated with cardiorespiratory arrest and death.
Not for IV use. Cephalosporin, imipenem, or other allergy: not recommended. Asthma. Monitor renal and hematopoietic function in prolonged use. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. May cause false (+) glucose test with Clinitest.
Rash, drug fever, serum sickness, anaphylaxis, blood dyscrasias, neuropathy, nephropathy, inj site reactions.
C–R Tubex 600,000 units/mL (1mL, 2mL)—10 (w. 1 inch or 1.25 inch needles); C–R disposable syringe 600,000 units/mL (4mL)—10 (w. 2 inch needles); C–R 900/300 Tubex 1.2 million units/syringe (2mL)—10 (w. 1 inch or 1.25 inch needles)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline